BACKGROUND: Nijmegen breakage syndrome (NBS) is a combined primary immunodeficiency with DNA repair defect, microcephaly, and other phenotypical features. It predominantly occurs in Slavic populations that have a high frequency of carriers with the causative NBN gene c.657_661del5 mutation. Due to the rarity of the disease in the rest of the world, studies of NBS patients are few. Here, we report a prospective study of a cohort of Russian NBS patients. METHODS: 35 Russian NBS patients of ages 1-19 years, referred to our Center between years 2012 and 2016, were prospectively studied. RESULTS: Despite the fact that in 80% of the patients microcephaly was diagnosed at birth or shortly thereafter, the average delay of NBS diagnosis was 6.5 years. Though 80% of the patients had laboratory signs of immunodeficiency, only 51% of the patients experienced significant infections. Autoimmune complications including interstitial lymphocytic lung disease and skin granulomas were noted in 34%, malignancies-in 57% of the patients. T-cell excision circle (TREC)/kappa-deleting recombination excision circle (KREC) levels were low in the majority of patients studied. Lower KREC levels correlated with autoimmune and oncological complications. Fifteen patients underwent hematopoietic stem cell transplantation (HSCT), 10 of them were alive and well, with good graft function. Three patients in the HSCT group and five non-transplanted patients died; tumor progression being the main cause of death. The probability of the overall survival since NBS diagnosis was 0.76 in the HSCT group and 0.3 in the non-transplanted group. CONCLUSION: Based on our findings of low TRECs in most NBS patients, independent of their age, TREC detection can be potentially useful for detection of NBS patients during neonatal screening. KREC concentration can be used as a prognostic marker of disease severity. HSCT is a viable treatment option in NBS and should be especially considered in patients with low KREC numbers early on, before development of life-threatening complications.
BACKGROUND:Nijmegen breakage syndrome (NBS) is a combined primary immunodeficiency with DNA repair defect, microcephaly, and other phenotypical features. It predominantly occurs in Slavic populations that have a high frequency of carriers with the causative NBN gene c.657_661del5 mutation. Due to the rarity of the disease in the rest of the world, studies of NBSpatients are few. Here, we report a prospective study of a cohort of Russian NBSpatients. METHODS: 35 Russian NBSpatients of ages 1-19 years, referred to our Center between years 2012 and 2016, were prospectively studied. RESULTS: Despite the fact that in 80% of the patientsmicrocephaly was diagnosed at birth or shortly thereafter, the average delay of NBS diagnosis was 6.5 years. Though 80% of the patients had laboratory signs of immunodeficiency, only 51% of the patients experienced significant infections. Autoimmune complications including interstitial lymphocytic lung disease and skin granulomas were noted in 34%, malignancies-in 57% of the patients. T-cell excision circle (TREC)/kappa-deleting recombination excision circle (KREC) levels were low in the majority of patients studied. Lower KREC levels correlated with autoimmune and oncological complications. Fifteen patients underwent hematopoietic stem cell transplantation (HSCT), 10 of them were alive and well, with good graft function. Three patients in the HSCT group and five non-transplanted patients died; tumor progression being the main cause of death. The probability of the overall survival since NBS diagnosis was 0.76 in the HSCT group and 0.3 in the non-transplanted group. CONCLUSION: Based on our findings of low TRECs in most NBSpatients, independent of their age, TREC detection can be potentially useful for detection of NBSpatients during neonatal screening. KREC concentration can be used as a prognostic marker of disease severity. HSCT is a viable treatment option in NBS and should be especially considered in patients with low KREC numbers early on, before development of life-threatening complications.
Authors: R Varon; E Seemanova; K Chrzanowska; O Hnateyko; D Piekutowska-Abramczuk; M Krajewska-Walasek; J Sykut-Cegielska; K Sperling; A Reis Journal: Eur J Hum Genet Date: 2000-11 Impact factor: 4.246
Authors: Helen V New; C M Cale; M Tischkowitz; A Jones; P Telfer; P Veys; A D'Andrea; C G Mathew; I Hann Journal: Pediatr Blood Cancer Date: 2005-05 Impact factor: 3.167
Authors: R Varon; C Vissinga; M Platzer; K M Cerosaletti; K H Chrzanowska; K Saar; G Beckmann; E Seemanová; P R Cooper; N J Nowak; M Stumm; C M Weemaes; R A Gatti; R K Wilson; M Digweed; A Rosenthal; K Sperling; P Concannon; A Reis Journal: Cell Date: 1998-05-01 Impact factor: 41.582
Authors: Elena V Samochatova; Alexey A Maschan; Larisa N Shelikhova; Natalia V Myakova; Margarita B Belogurova; Olga P Khlebnikova; Anastasia V Shamardina; Olga V Ryskal; Julia V Roumiantseva; Dmitriy M Konovalov; Maria E Dubrovina; Alexander G Rumyantsev Journal: J Pediatr Hematol Oncol Date: 2014-07 Impact factor: 1.289
Authors: Ludmila Perelygina; Stanley Plotkin; Pierre Russo; Timo Hautala; Francisco Bonilla; Hans D Ochs; Avni Joshi; John Routes; Kiran Patel; Claudia Wehr; Joseph Icenogle; Kathleen E Sullivan Journal: J Allergy Clin Immunol Date: 2016-09-06 Impact factor: 10.793
Authors: Jay P Patel; Jennifer M Puck; Rajgopal Srinivasan; Christina Brown; Uma Sunderam; Kunal Kundu; Steven E Brenner; Richard A Gatti; Joseph A Church Journal: J Clin Immunol Date: 2015-02-13 Impact factor: 8.317
Authors: David Buchbinder; Fabian Hauck; Michael H Albert; Anita Rack; Shahrzad Bakhtiar; Anna Shcherbina; Elena Deripapa; Kathleen E Sullivan; Ludmila Perelygina; Marc Eloit; Bénédicte Neven; Philippe Pérot; Despina Moshous; Félipe Suarez; Christine Bodemer; Francisco A Bonilla; Louise E Vaz; Alfons L Krol; Christoph Klein; Mikko Seppanen; Diane J Nugent; Jasjit Singh; Hans D Ochs Journal: J Clin Immunol Date: 2019-01-03 Impact factor: 8.317
Authors: M Dasouki; A Jabr; G AlDakheel; F Elbadaoui; A M Alazami; B Al-Saud; R Arnaout; H Aldhekri; I Alotaibi; H Al-Mousa; A Hawwari Journal: Clin Exp Immunol Date: 2020-07-21 Impact factor: 4.330
Authors: Przemysław Gałązka; Krzysztof Czyżewski; Anna Szaflarska-Popławska; Robert Dębski; Anna Krenska; Jan Styczyński Journal: Cent Eur J Immunol Date: 2019-09-30 Impact factor: 2.085
Authors: Janne Strand; Kiran Aftab Gul; Hans Christian Erichsen; Emma Lundman; Mona C Berge; Anette K Trømborg; Linda K Sørgjerd; Mari Ytre-Arne; Silje Hogner; Ruth Halsne; Hege Junita Gaup; Liv T Osnes; Grete A B Kro; Hanne S Sorte; Lars Mørkrid; Alexander D Rowe; Trine Tangeraas; Jens V Jørgensen; Charlotte Alme; Trude E H Bjørndalen; Arild E Rønnestad; Astri M Lang; Terje Rootwelt; Jochen Buechner; Torstein Øverland; Tore G Abrahamsen; Rolf D Pettersen; Asbjørg Stray-Pedersen Journal: Front Immunol Date: 2020-07-09 Impact factor: 7.561